Literature DB >> 16015630

RET gene rearrangements (RET/PTC1 and RET/PTC3) in papillary thyroid carcinomas from an iodine-rich country (Japan).

Tadao Nakazawa1, Tetsuo Kondo, Yoshihiko Kobayashi, Noboru Takamura, Shin-ichi Murata, Kaori Kameyama, Akira Muramatsu, Kohichi Ito, Makio Kobayashi, Ryohei Katoh.   

Abstract

BACKGROUND: The frequency of RET rearrangements (RET/PTC) in papillary thyroid carcinomas varies significantly according to geographic area, with the greatest incidence reported in the Belarus region, which is iodine-deficient and was contaminated severely after the Chernobyl reactor accident, and with the lowest incidence in iodine-rich, nonirradiated Japan. The authors investigated the prevalence of RET/PTC in a large number of thyroid tumors from Japanese patients.
METHODS: Fresh and paraffin embedded tumor tissues from 215 Japanese patients were examined for RET rearrangements (RET/PTC1 and RET/PTC3) by means of reverse transcriptase-polymerase chain reaction analysis, with primers flanking the chimeric region, followed by direct-sequence analysis.
RESULTS: RET/PTC was found only in papillary carcinomas and was not observed in other histologic types of thyroid tumors. The overall frequency of RET/PTC in papillary carcinomas was 28.4%, with a greater frequency in younger patients, including 41.9% of younger patients age < 20 years, 27.6% of patients age 20-40 years, and 24.8% of patients age > 40 years. Among the patients in these 3 age groups, the prevalence rate of RET/PTC1 was similar, but RET/PTC3 was observed most frequently among patients age < 20 years. When the tumors were grouped further according to histologic subtypes, the prevalence of RET/PTC3 was greater in solid/solid-follicular papillary carcinomas than in classic papillary carcinomas.
CONCLUSIONS: The results indicated that RET/PTC may be useful as a specific molecular marker for papillary thyroid carcinomas. Furthermore, its incidence in such tumors was not low in Japanese patients, and it seemed to be associated with patient age. Therefore, the current results raise questions regarding the belief that the frequency of RET/PTC differs geographically and is especially low in Japan.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16015630     DOI: 10.1002/cncr.21270

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  21 in total

Review 1.  Current controversies and future directions in the diagnosis and management of differentiated thyroid cancers.

Authors:  Timothy M Ullmann; Katherine D Gray; Maureen D Moore; Rasa Zarnegar; Thomas J Fahey
Journal:  Gland Surg       Date:  2018-10

2.  High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma.

Authors:  Ying C Henderson; Thomas D Shellenberger; Michelle D Williams; Adel K El-Naggar; Mitchell J Fredrick; Kathleen M Cieply; Gary L Clayman
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

3.  Animal models of cancer in the head and neck region.

Authors:  Seungwon Kim
Journal:  Clin Exp Otorhinolaryngol       Date:  2009-06-27       Impact factor: 3.372

4.  RET/PTC rearrangements arising from a small population of papillary thyroid carcinoma cells, possible candidate for passenger mutation.

Authors:  Tadao Nakazawa; Shin-ichi Murata; Tetsuo Kondo; Dongfeng Niu; Kunio Mochizuki; Tomonori Kawasaki; Tetsu Yamane; Nobuki Nakamura; Ryohei Katoh
Journal:  Virchows Arch       Date:  2009-06-03       Impact factor: 4.064

Review 5.  RET and neuroendocrine tumors.

Authors:  Yoshiki Murakumo; Mayumi Jijiwa; Naoya Asai; Masatoshi Ichihara; Masahide Takahashi
Journal:  Pituitary       Date:  2006       Impact factor: 3.599

6.  Clinical, genetic, and immunohistochemical characterization of 70 Ukrainian adult cases with post-Chornobyl papillary thyroid carcinoma.

Authors:  Andrii Dinets; Mykola Hulchiy; Anastasios Sofiadis; Mehran Ghaderi; Anders Höög; Catharina Larsson; Jan Zedenius
Journal:  Eur J Endocrinol       Date:  2012-03-28       Impact factor: 6.664

7.  Multicentric occurrence of multiple papillary thyroid carcinomas--HUMARA and BRAF mutation analysis.

Authors:  Tadao Nakazawa; Tetsuo Kondo; Ippei Tahara; Kazunari Kasai; Tomohiro Inoue; Naoki Oishi; Kunio Mochizuki; Takeo Kubota; Ryohei Katoh
Journal:  Cancer Med       Date:  2015-04-17       Impact factor: 4.452

Review 8.  Clinical Indications for Treatment with Multi-Kinase Inhibitors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer.

Authors:  Naoki Fukuda; Shunji Takahashi
Journal:  Cancers (Basel)       Date:  2021-05-10       Impact factor: 6.639

9.  The clinical features of papillary thyroid cancer in Hashimoto's thyroiditis patients from an area with a high prevalence of Hashimoto's disease.

Authors:  Ling Zhang; Hui Li; Qing-hai Ji; Yong-xue Zhu; Zhuo-ying Wang; Yu Wang; Cai-ping Huang; Qiang Shen; Duan-shu Li; Yi Wu
Journal:  BMC Cancer       Date:  2012-12-21       Impact factor: 4.430

10.  Human thyroid tumours, the puzzling lessons from E7 and RET/PTC3 transgenic mice.

Authors:  L Jin; A Burniat; J-E Dumont; F Miot; B Corvilain; B Franc
Journal:  Br J Cancer       Date:  2008-11-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.